1. Home
  2. HDL vs RZLT Comparison

HDL vs RZLT Comparison

Compare HDL & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

HOLD

Current Price

$18.32

Market Cap

1.1B

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$10.42

Market Cap

997.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
RZLT
Founded
2016
2010
Country
Singapore
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
997.7M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
HDL
RZLT
Price
$18.32
$10.42
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$15.33
AVG Volume (30 Days)
2.0K
1.6M
Earning Date
11-26-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$820,865,000.00
N/A
Revenue This Year
$11.19
N/A
Revenue Next Year
$13.37
N/A
P/E Ratio
$58.13
N/A
Revenue Growth
8.02
N/A
52 Week Low
$16.30
$2.22
52 Week High
$30.00
$11.46

Technical Indicators

Market Signals
Indicator
HDL
RZLT
Relative Strength Index (RSI) 54.50 61.40
Support Level $17.66 $8.84
Resistance Level $17.77 $9.82
Average True Range (ATR) 0.31 0.64
MACD 0.13 -0.01
Stochastic Oscillator 99.34 83.58

Price Performance

Historical Comparison
HDL
RZLT

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: